A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

BACKGROUND. Dysregulated hepatocyte growth factor/mesenchymal‐epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular endothelial growth factor inhibition in metastatic colorectal cancer (mCRC). We report outcomes from a double‐blind, multicenter phase II t...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Oncologist
Main Authors: Bendell, Johanna C., Hochster, Howard, Hart, Lowell L., Firdaus, Irfan, Mace, Joseph R., McFarlane, Joshua J., Kozloff, Mark, Catenacci, Daniel, Hsu, Jessie J., Hack, Stephen P., Shames, David S., Phan, See‐Chun, Koeppen, Hartmut, Cohn, Allen L.
Formáid: Artigo
Teanga:Inglês
Foilsithe: AlphaMed Press 2017
Ábhair:
Gastrointestinal Cancer
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344636/
https://ncbi.nlm.nih.gov/pubmed/28209746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0223
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla